SFE Investment Counsel Has $1.81 Million Stake in Pfizer Inc. (NYSE:PFE)

SFE Investment Counsel increased its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 18.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 71,418 shares of the biopharmaceutical company's stock after buying an additional 11,088 shares during the quarter. SFE Investment Counsel's holdings in Pfizer were worth $1,810,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in PFE. Clarity Asset Management Inc. bought a new position in Pfizer during the fourth quarter worth $27,000. Gould Capital LLC boosted its position in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. North Capital Inc. bought a new position in Pfizer during the first quarter worth $28,000. Bernard Wealth Management Corp. bought a new position in Pfizer during the fourth quarter worth $30,000. Finally, Horizon Financial Services LLC bought a new position in Pfizer during the first quarter worth $35,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Trading Up 0.1%

PFE stock traded up $0.01 during trading on Thursday, hitting $25.37. The company had a trading volume of 25,643,723 shares, compared to its average volume of 38,513,248. The stock has a market cap of $144.25 billion, a PE ratio of 18.39, a PEG ratio of 0.92 and a beta of 0.58. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The business has a 50-day moving average of $24.26 and a 200-day moving average of $24.70. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business's quarterly revenue was down 7.8% on a year-over-year basis. During the same period last year, the company posted $0.82 earnings per share. Research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.78%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is 124.64%.

Wall Street Analyst Weigh In

A number of equities analysts have commented on PFE shares. BMO Capital Markets reduced their price objective on shares of Pfizer from $36.00 to $30.00 in a research report on Thursday, April 17th. TD Cowen dropped their target price on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a report on Tuesday, April 22nd. Leerink Partners dropped their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Redburn Atlantic dropped their target price on Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Finally, Morgan Stanley lifted their target price on Pfizer from $31.00 to $32.00 and gave the stock an "equal weight" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and three have given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.